Cerenome, Inc.
Stock
Stock
Ticker: PSTV
PSTV
Price
Price
CHART BY
Frequently asked questions
What is Cerenome, Inc.'s market capitalization?
The market capitalization of Cerenome, Inc. is $12.83M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Cerenome, Inc.?
Cerenome, Inc.'s Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$4.41. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Cerenome, Inc.'s stock?
Currently, 2 analysts cover Cerenome, Inc.'s stock, with a consensus target price of $37.00. Analyst ratings provide insights into the stock's expected performance.
What is Cerenome, Inc.'s revenue over the trailing twelve months?
Over the trailing twelve months, Cerenome, Inc. reported a revenue of $4.20M.
What is the EBITDA for Cerenome, Inc.?
Cerenome, Inc.'s Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$25.96M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Cerenome, Inc.?
Cerenome, Inc. has a free cash flow of -$23.55M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Cerenome, Inc. have, and what sector and industry does it belong to?
Cerenome, Inc. employs approximately 28 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Cerenome, Inc.'s shares?
The free float of Cerenome, Inc. is 7.49M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $12.83M
- EPS (TTM)
- -$4.41
- Free Float
- 7.49M
- Revenue (TTM)
- $4.20M
- EBITDA (TTM)
- -$25.96M
- Free Cashflow (TTM)
- -$23.55M
Pricing
- 52W span
- $1.485$18.82
Analyst Ratings
The price target is $37.00 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
Cerenome, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
- Employees
- 28
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- PSTV
Fundamentals & EOD data from FactSet